Month: September 2025

PRESS RELEASE Arcadis’ shareholders appoint Simon Crowe as new CFO and member of the Executive Board Amsterdam, 30 September 2025 – Arcadis (EURONEXT: ARCAD), a global leader in sustainable design, engineering, and consultancy solutions, confirms the appointment of Simon Crowe for the position of Chief Financial Officer and member of the Executive Board. Simon Crowe was appointed to the Executive Board of Arcadis for a period of four years and will commence his role as CFO of Arcadis with immediate effect. His nomination was announced on 5 August 2025. Financial Calendar30 October 2025 – Third Quarter 2025 Trading Update 19 February 2026 –Fourth Quarter and Full Year 2025 Results 30 April 2026 – First Quarter 2026 Trading UpdateArcadis IR investor calendar: https://www.arcadis.com/en/investors/investor-calendar ARCADIS INVESTOR...

VANCOUVER, British Columbia, Sept. 30, 2025 (GLOBE NEWSWIRE) — Liberty Gold Corp. (TSX: LGD; OTCQX: LGDTF) (“Liberty Gold” or the “Company”), is pleased to announce that it has closed its previously announced private placement (the “Placement”) with Centerra Gold Inc. (“Centerra”), whereby Centerra will acquire 9.9% of the issued and outstanding common shares of the Company (the “Common Shares”). Pursuant to the Placement, Centerra acquired 50,025,230 common shares of Liberty Gold at a price of C$0.56 per Common Share for gross proceeds of approximately C$28.01 million. The issue price represented a 10% premium to the 5-day volume weighted average price of the Common Shares as traded on the Toronto Stock Exchange (“TSX”) prior to announcement of the transaction. The net proceeds from the Placement will be used to advance...

BEIJING, Sept. 30, 2025 (GLOBE NEWSWIRE) — Zhihu Inc. (“Zhihu” or the “Company”) (NYSE: ZH; HKEX: 2390), a leading online content community in China, today announced the resignation of Mr. Bin Sun from his position as the Company’s chief technology officer due to personal reasons, effective from September 30, 2025. “On behalf of our board and management team, I extend our sincere gratitude to Mr. Sun for his valuable contribution as our chief technology officer,” commented Mr. Yuan Zhou, chairman of the board and chief executive officer of the Company. “We wish him all the best in his future endeavors.” About Zhihu Inc. Zhihu Inc. (NYSE: ZH; HKEX: 2390) is a leading online content community where people come to find solutions, make decisions, seek inspiration, and have fun. Since the initial launch in 2010, Zhihu has grown into...

ST. JOHN’S, Newfoundland and Labrador, Sept. 30, 2025 (GLOBE NEWSWIRE) — Fortis Inc. (“Fortis” or the “Corporation”) (TSX/NYSE: FTS) will release its third quarter 2025 financial results and new five-year capital outlook for the period 2026-2030 on Tuesday, November 4, 2025. A teleconference and webcast will be held the same day at 8:30 a.m. (Eastern). David Hutchens, President and Chief Executive Officer and Jocelyn Perry, Executive Vice President and Chief Financial Officer will discuss the Corporation’s third quarter financial results and five-year capital outlook. Shareholders, analysts, members of the media and other interested parties are invited to listen to the teleconference via the live webcast on the Corporation’s website, www.fortisinc.com/‌investors/‌‌‌‌events-and-presentations. Those...

SOL-1 superiority trial continues to demonstrate outstanding patient retention and protocol adherence, with no new or unexpected safety signals observed to date; topline data on track for 1Q 2026 Event to detail how robust SOL-R patient selection strategy, trial design, and potential SOL-1 success could drive confidence in SOL-R outcomes; topline data on track for 1H 2027 Will showcase planned HELIOS-2 and HELIOS-3 registrational trials to evaluate AXPAXLI in non-proliferative diabetic retinopathy (NPDR) using novel primary endpoint, aligned with FDA in HELIOS-2 Special Protocol Assessment (SPA) agreement To outline SOL-X open label extension program and AXPAXLI’s potential to improve long-term outcomes and expand the retinal vascular disease market The live event will begin at 2:00 PM ET in New York City with virtual access available BEDFORD,...

ORION CORPORATION PRESS RELEASE 30 SEPTEMBER 2025 at 13.00 EEST         Orion’s phase 2 study of ODM-105 in insomnia did not meet primary goal Orion to discontinue development of ODM-105 for insomnia. ODM-105 (tasipimidine) was well tolerated. Detailed results, including safety data, and their assessment are to be finalized.Orion Corporation today announced that its candidate ODM-105 (tasipimidine) did not meet the primary goal in the clinical Phase 2 UNITAS study for the treatment of patients with insomnia. According to the study results, ODM-105 did not significantly improve insomnia-related symptoms such as time to fall asleep or sleep duration compared with placebo. ODM-105 was generally safe and well tolerated. Detailed results, including safety data, and their assesment are not yet finalized. “We are disappointed that our...

Clinical benefit for efzofitimod across multiple disease-related health outcomes reported. Improvement in Fatigue Assessment Scale Total Score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo (p=0.0226). Improvement in King’s Sarcoidosis Questionnaire-General Health score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo (p=0.0197). SAN DIEGO, Sept. 30, 2025 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today presented additional findings from the Phase 3 EFZO-FIT™ study of efzofitimod in 268 patients with pulmonary sarcoidosis, a major form of interstitial lung disease, in a late-breaking...

No offers were received in the reverse auction buyback, and therefore the company will initiate standard share buyback in accordance with the buyback program. The number of shares to be acquired under the buy-back program will be up to 2,250,000, at a total purchase price which may not exceed ISK 750,000,000. The execution of the buy-back program must comply with the Act on Public Limited Companies, No. 2/1995. In addition, the buy-back program will be implemented in accordance with Regulation (EU) No. 596/2014 on market abuse, as well as Commission Delegated Regulation (EU) 2016/1052 with regard to regulatory technical standards for the conditions applicable to buy-back programmes, and the Icelandic Act on Measures Against Market Abuse No. 60/2021. Eimskip currently owns 1.725.320 own shares, equivalent to 1.04% of the company‘s share...

SINGAPORE, Sept. 30, 2025 (GLOBE NEWSWIRE) — EngageLab, a world-leading AI-powered omnichannel customer engagement solution provider, today announced the successful deployment of its AppPush and WhatsApp Business API solutions for E-GetS, a leading Southeast Asian local services and e-commerce platform. The partnership has driven significant improvements in user engagement, operational efficiency, and business growth across Cambodia, Laos, Thailand, and Vietnam. About E-GetS E-GetS is a leading Southeast Asian local services and e-commerce platform, operating across Cambodia, Laos, Thailand, and Vietnam. With over 3 million app downloads, E-GetS offers a wide range of services—including food delivery, group buying, e-commerce, and digital payment solutions—serving millions of users in a highly multilingual and multicultural environment.Challenges...